Blog

Ryan Moy: Our investigator-initiated trial for diffuse gastric cancer after progression on first-line therapy is now open at Columbia!

Photo taken from doctors.columbia.edu

May 24, 2024, 14:22

Ryan Moy: Our investigator-initiated trial for diffuse gastric cancer after progression on first-line therapy is now open at Columbia!

Ryan Moy, Assistant Professor of Medicine and Medical Oncologist at Columbia University Irving Medical Center, made the following post on X:

“Our investigator-initiated trial targeting the FAK and MAPK pathways with defactinib and avutometinib for patients with diffuse gastric cancer after progression on first-line therapy is now open at Columbia!”

Read the article.
Source: Ryan Moy/X
.

Assistant Professor of Medicine avutometinib cancer Cancer research clinical trial Columbia University Irving Medical Center defactinib diffuse gastric cancer FAK pathway first-line therapy Healthcare Innovation investigator-initiated trial MAPK pathway medical oncology OncoDaily Oncology Research Ryan Moy

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Special Coverage